Примери за използване на Serum phosphate на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
In individuals without risk factors for renal disease, it is recommended that renal function(creatinine clearance and serum phosphate) is monitored after two to four weeks of use,
That if serum phosphate is confirmed to be<
8.0 mg/dl(2.0 mmol/l) and serum phosphate to 2.0 mg/dl(0.65 mmol/l)
After initiation of treatment with burosumab, fasting serum phosphate should be measured every 2 weeks for the first month of treatment,
However, the incidences of decreases in serum calcium to< 8.0 mg/ dl(2.0 mmol/ l) and serum phosphate to≤ 2.0 mg/ dl(0.65 mmol/ l) were similar in both treatment groups.
If fasting serum phosphate is below the reference range for age, the dose may be
Serum phosphate levels should be closely monitored and the dose of Renagel adjusted accordingly with the goal of lowering serum phosphate to 1.76 mmol/ l(5.5mg/ dl) or less.
Renal function(creatinine clearance and serum phosphate) should be evaluated prior to initiating Truvada for treatment of HIV-1
If fasting serum phosphate is above the reference range for age, the next dose should be withheld
decreases in serum phosphate, uric acid
Renal function(creatinine clearance and serum phosphate) should be evaluated prior to initiating emtricitabine/tenofovir disoproxil for treatment of HIV-1
it is recommended that fasting serum phosphate is targeted in the lower end of the normal reference range for age(see section 4.4).
In a murine model of XLH, a significant reduction in the incidence of ectopic mineralisation was observed at equivalent levels of serum phosphate, suggesting that the risk of mineralisation is less in the presence of excess FGF23.
Creatinine clearance, serum phosphate, urine glucose and urine protein should
a direct PK-PD relationship between serum burosumab concentrations and increases in serum phosphate concentration is observed and well described by an Emax/EC50 model.
therapy with Truvada and renal function(creatinine clearance and serum phosphate) is also monitored every four weeks during the first year and then every three months.
that renal function(creatinine clearance and serum phosphate) be monitored every four weeks during the first year
tenofovir disoproxil fumarate and renal function(creatinine clearance and serum phosphate) is also monitored every four weeks during the first year, and then every three months.
bone toxicity and a decrease in serum phosphate concentration.
That if serum phosphate is confirmed to be<